2022年3月14日简报:上海昨日新增本土新冠肺炎确诊病例41+128例;张文宏认为这波疫情是倒春寒;全球疫情反弹,德尔塔克戎(deltacron)变体引发关注

2022-03-14 网络 网络

截至北京时间2022年3月14日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿5815万例,新增1,326,606例,达到458,152

截至北京时间2022年3月14日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过4亿5815万例,新增1,326,606例,达到458,152,169例。累计死亡病例606.5万例,达到6,065,718例。新增死亡为3,509例。康复为391,484,612例,重症和危重症病人达到65,464例;全球新冠确诊病例超过100万例的国家和地区达56个,125个国家和地区病例超10万例。昨日报道:2022年3月13日简报:香港新增15789例确诊病例,疫情快速回落;英国新冠病死率与流感相当;韩国新增38万例病例,死亡269人;

上海昨日新增本土新冠肺炎确诊病例41+128例

上海市卫健委今早(14日)通报:2022年3月13日0—24时,新增本土新冠肺炎确诊病例41例(含2例由无症状感染者转为确诊病例)和无症状感染者128例,其中2例本土确诊病例为此前的无症状感染者转归,32例本土确诊病例和90例无症状感染者在隔离管控中发现,其余在相关风险人群排查中发现。新增境外输入性新冠肺炎确诊病例16例和无症状感染者2例,均在闭环管控中发现。

2022年3月13日0—24时,新增本土新冠肺炎确诊病例41例,含2例由无症状感染者转为确诊病例。

杭州部分地区开始免费发放新冠抗原自测试剂

3月13日晚,杭州市余杭区、上城区有小区业主在业主群接到紧急通知,为防控疫情,当晚开展新冠病毒抗原自检工作,检测办法为上门发放工具自测。据了解,余杭区为多个小区发放的免费自测产品中,有余杭区上市公司博拓生物生产的RightSign新冠抗原快速检测试剂。也有小区业主收到的抗原自测试剂是杭州莱和生物技术有限公司生产的自检试剂盒。

美国前总统奥巴马新冠病毒检测结果呈阳性

美国前总统奥巴马3月13日说,他新冠病毒检测结果呈阳性。

奥巴马当天在社交媒体上发文说,他近期感觉喉咙发痒,除此之外感觉良好。他和夫人米歇尔都已完成新冠疫苗接种,并接种了加强针。米歇尔新冠病毒检测结果呈阴性。

奥巴马1961年出生,曾于2009年至2017年担任美国总统。

美疾控中心:98%的美国人口无需戴口罩

美国疾病控制与预防中心(CDC)表示,美国约98%的人口生活在新冠疫情传播水平足够低的地区,居住在这些地区的人们不需要在室内戴口罩。

美疾控预防中心:美国两年多来已有1567名儿童死于新冠肺炎

美国疾病控制与预防中心的数据显示,今年年初以来,美国已有550名儿童死于新冠肺炎,此前22个月的死亡病例为1017人。

芝加哥大学医学中心科默儿童医院儿科重症专家杰森表示:“在奥密克戎扩散期间,住院患儿大规模激增。”报道称,奥密克戎对儿童的影响可能与此前变异毒株不同。它往往会影响儿童的上呼吸道,因为上呼吸道较窄,儿童更容易受到刺激。“说新冠肺炎死亡现象只出现在不健康的儿童或有风险因素的儿童身上,从数据来看,这并不准确。”

香港新增32430例新冠肺炎确诊病例

香港特区政府卫生署卫生防护中心13日公布,截至当日零时,香港新增32430例确诊的新冠肺炎病例,其中经核酸检测确诊病例13335例。

3月12日,新冠病毒快速抗原测试阳性结果人士申报系统接获19095例呈报病例。

据香港医管局介绍,过去24小时,有190名确诊患者在公立医院离世。

香港12岁以上新冠疫苗第二剂接种率达八成

香港特区政府公务员事务局局长聂德权13日在社交平台发文表示,经过社会及市民的共同努力,香港达成12岁以上第二剂新冠疫苗接种率八成的阶段性目标,接种人数逾539万。

聂德权表示,下一步,香港将会把第二剂疫苗接种率推高至九成,亦希望在4月中做到儿童接种率达九成,同时会加快第三剂疫苗接种。

长者首剂疫苗接种率亦有持续上升,聂德权表示,60至69岁首剂疫苗接种率达89%、70至79岁长者首剂疫苗接种率已逾八成、80岁或以上长者首剂疫苗接种率达54.6%。

新冠病毒“德尔塔克戎”(deltacron)变体确实存在

法国科学家通过基因组测序首次证实,此前已引起不少关注的新冠病毒“德尔塔克戎”(deltacron)变体确实存在,其结合了新冠病毒德尔塔变体和奥密克戎变体中的变异。目前,美国和欧洲都报告了相关病例。

法国马赛地中海传染病医疗和教学研究所研究人员3月8日在医学研究论文预印本网站medRxiv上发表文章称,他们通过基因组测序确认了这一新变体的存在。而且,该变体已在法国多个地区被检测到。

另外,全球流感共享数据库(GISAID)提供的数据显示,丹麦和荷兰也发现了“德尔塔克戎”相关病例。总部位于加利福尼亚州的基因研究公司Helix在美国发现了两例。据英国《卫报》报道,英国已经确认了约30例“德尔塔克戎”病例。而且,据GISAID称,这种新变体可能从1月份就开始在人群中传播了。

张文宏凌晨发文:倒春寒

我们统计的上海近六个月收治的2266例病例中,大多数是海外输入性病例,94%打过疫苗。这2266个病人中,重症的只有0.1%,危重症(需要插管)和死亡的一例也没有。有人说病人中94%的打了疫苗还感染,说明疫苗没有用。这就不讲道理了。现在国际旅行的人疫苗接种率很高,达到90%以上,其中不到5%的入境时候被筛查出来有核酸阳性。你去看这感染的5%的人,当然是大多数打过疫苗,这可以理解为打了疫苗仍有突破感染的机会。但是重症率与死亡率真的低于流感了。

近期我国继续采取社会面清零策略,将传播极快的奥密克戎第五波疫情压制在完全可控的水平是非常重要的。但这并不意味着我们会持久性地采取封城和全检测的策略。

全球疫情反弹

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033765, encodeId=2a6c2033e65ea, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 09 05:19:54 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668786, encodeId=74ff1668e868e, content=<a href='/topic/show?id=b3e81e0760f' target=_blank style='color:#2F92EE;'>#TACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17076, encryptionId=b3e81e0760f, topicName=TACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30c526418667, createdName=ligang4448, createdTime=Wed Oct 26 02:19:54 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858017, encodeId=f8a6185801efe, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Dec 11 13:19:54 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400515, encodeId=30cb14005155c, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526012, encodeId=70041526012cf, content=<a href='/topic/show?id=81c93e74709' target=_blank style='color:#2F92EE;'>#反弹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37747, encryptionId=81c93e74709, topicName=反弹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17d711676114, createdName=meichuangyi, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-08-09 柳叶一刀
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033765, encodeId=2a6c2033e65ea, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 09 05:19:54 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668786, encodeId=74ff1668e868e, content=<a href='/topic/show?id=b3e81e0760f' target=_blank style='color:#2F92EE;'>#TACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17076, encryptionId=b3e81e0760f, topicName=TACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30c526418667, createdName=ligang4448, createdTime=Wed Oct 26 02:19:54 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858017, encodeId=f8a6185801efe, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Dec 11 13:19:54 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400515, encodeId=30cb14005155c, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526012, encodeId=70041526012cf, content=<a href='/topic/show?id=81c93e74709' target=_blank style='color:#2F92EE;'>#反弹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37747, encryptionId=81c93e74709, topicName=反弹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17d711676114, createdName=meichuangyi, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-10-26 ligang4448
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033765, encodeId=2a6c2033e65ea, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 09 05:19:54 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668786, encodeId=74ff1668e868e, content=<a href='/topic/show?id=b3e81e0760f' target=_blank style='color:#2F92EE;'>#TACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17076, encryptionId=b3e81e0760f, topicName=TACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30c526418667, createdName=ligang4448, createdTime=Wed Oct 26 02:19:54 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858017, encodeId=f8a6185801efe, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Dec 11 13:19:54 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400515, encodeId=30cb14005155c, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526012, encodeId=70041526012cf, content=<a href='/topic/show?id=81c93e74709' target=_blank style='color:#2F92EE;'>#反弹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37747, encryptionId=81c93e74709, topicName=反弹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17d711676114, createdName=meichuangyi, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033765, encodeId=2a6c2033e65ea, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 09 05:19:54 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668786, encodeId=74ff1668e868e, content=<a href='/topic/show?id=b3e81e0760f' target=_blank style='color:#2F92EE;'>#TACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17076, encryptionId=b3e81e0760f, topicName=TACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30c526418667, createdName=ligang4448, createdTime=Wed Oct 26 02:19:54 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858017, encodeId=f8a6185801efe, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Dec 11 13:19:54 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400515, encodeId=30cb14005155c, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526012, encodeId=70041526012cf, content=<a href='/topic/show?id=81c93e74709' target=_blank style='color:#2F92EE;'>#反弹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37747, encryptionId=81c93e74709, topicName=反弹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17d711676114, createdName=meichuangyi, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-03-15 10518094zz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033765, encodeId=2a6c2033e65ea, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 09 05:19:54 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668786, encodeId=74ff1668e868e, content=<a href='/topic/show?id=b3e81e0760f' target=_blank style='color:#2F92EE;'>#TACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17076, encryptionId=b3e81e0760f, topicName=TACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30c526418667, createdName=ligang4448, createdTime=Wed Oct 26 02:19:54 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858017, encodeId=f8a6185801efe, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Dec 11 13:19:54 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400515, encodeId=30cb14005155c, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526012, encodeId=70041526012cf, content=<a href='/topic/show?id=81c93e74709' target=_blank style='color:#2F92EE;'>#反弹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37747, encryptionId=81c93e74709, topicName=反弹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17d711676114, createdName=meichuangyi, createdTime=Tue Mar 15 23:19:54 CST 2022, time=2022-03-15, status=1, ipAttribution=)]

相关资讯

2022年3月13日简报:香港新增15789例确诊病例,疫情快速回落;英国新冠病死率与流感相当;韩国新增38万例病例,死亡269人;吉林省单日新增本土新冠肺炎确诊病例1412例

截至北京时间2022年3月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿5630万例,新增1,248,418例,达到456,306

梅斯科普:面对疫情,千万不要恐慌、害怕、过度焦虑!恐慌的危害不亚于疫情本身

近日,国内本土病例新增较快,弥漫着普遍的焦虑。人们在相互交流,在微信群,朋友圈,都在讨论疫情。同样,梅斯小编在百度上搜索“疫情让我很”,看下面提示就知道,全部是一片焦虑!

吉林3月12日新增本土病例“1412+744”例,不应该过度恐慌

3月12日0时至24时,吉林省新增本土确诊病1412例,新增本土无症状感染者744例。

张文宏:凌晨发文,抗疫两年以来最困难的时期,是漫长冬夜还是倒春寒?

上海的精准防控在这次奥密克戎BA.2传播之际,由于发生突然,启动晚,病毒快,目前仍处于与病毒的并跑阶段,感到非常吃力。